|
EP2014283A4
(en)
|
2006-03-30 |
2010-04-21 |
Aichi Prefecture |
ANTI-INFLAMMATORY MEANS AND MEANS FOR PREVENTION OF CANCER WITH CANOLOL OR A PRODRUG THEREOF AND THEREOF CONTAINING PHARMACEUTICALS, COSMETICS AND FOODS
|
|
US20100029619A1
(en)
*
|
2006-08-04 |
2010-02-04 |
Takeda Pharmaceutical Company Limted |
Fused heterocyclic compound
|
|
JP5336375B2
(ja)
|
2006-08-30 |
2013-11-06 |
セルゾーム リミテッド |
キナーゼ阻害剤としてのトリアゾール誘導体
|
|
CA2672494A1
(en)
|
2006-12-14 |
2008-06-19 |
Nps Pharmaceuticals, Inc. |
Use of d-serine derivatives for the treatment of anxiety disorders
|
|
US8263585B2
(en)
|
2007-05-04 |
2012-09-11 |
Novartis Ag |
Organic compounds
|
|
AU2008282728B2
(en)
*
|
2007-08-02 |
2012-04-19 |
Amgen Inc. |
Pl3 kinase modulators and methods of use
|
|
UY31292A1
(es)
*
|
2007-08-14 |
2009-03-31 |
|
Imidazoles biciclicos fusionados
|
|
EP2062893A1
(en)
*
|
2007-10-18 |
2009-05-27 |
Bayer Schering Pharma AG |
Fused imidazoles for cancer treatment
|
|
AU2008289101A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Icagen, Inc. |
Heterocycles as potassium channel modulators
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
CA2691448A1
(en)
|
2007-08-31 |
2009-03-05 |
Dominique Swinnen |
Triazolopyridine compounds and their use as ask inhibitors
|
|
MX2010005700A
(es)
|
2007-11-27 |
2010-06-11 |
Cellzome Ltd |
Amino triazoles como inhibidores pi3k.
|
|
AU2008343813B2
(en)
*
|
2007-12-19 |
2012-04-12 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
|
US8268834B2
(en)
*
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
WO2009126635A1
(en)
*
|
2008-04-09 |
2009-10-15 |
Abbott Laboratories |
2-amino-benzothiazole derivates useful as inhibitors of rock kinases
|
|
EP2283013A1
(en)
|
2008-04-16 |
2011-02-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of phosphatidylinositol 3-kinase
|
|
EP2277881A4
(en)
|
2008-04-18 |
2011-09-07 |
Shionogi & Co |
HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
|
|
AR071523A1
(es)
*
|
2008-04-30 |
2010-06-23 |
Merck Serono Sa |
Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
|
|
WO2009155052A1
(en)
*
|
2008-05-28 |
2009-12-23 |
Wyeth |
3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
JP5599783B2
(ja)
|
2008-05-30 |
2014-10-01 |
アムジエン・インコーポレーテツド |
Ｐｉ３キナーゼの阻害薬
|
|
EP2288260A4
(en)
|
2008-06-20 |
2013-10-23 |
Genentech Inc |
TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
|
|
BRPI0909945A2
(pt)
|
2008-06-20 |
2015-07-28 |
Genentech Inc |
"composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
|
|
WO2010008847A2
(en)
*
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
WO2010007100A1
(en)
*
|
2008-07-15 |
2010-01-21 |
Cellzome Ltd |
7-substituted amino triazoles as pi3k inhibitors
|
|
WO2010007099A1
(en)
*
|
2008-07-15 |
2010-01-21 |
Cellzome Limited |
2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
|
|
WO2010057877A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Cellzome Limited |
7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
|
|
ES2663222T3
(es)
|
2008-12-19 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina útiles como inhibidores de la quinasa ATR
|
|
WO2010092015A1
(en)
|
2009-02-10 |
2010-08-19 |
Cellzome Limited |
Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
|
|
SG173610A1
(en)
|
2009-02-13 |
2011-09-29 |
Fovea Pharmaceuticals Sa |
[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
|
|
CA2752596A1
(en)
|
2009-02-17 |
2010-08-26 |
Vertex Pharmaceuticals Incorporated |
Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
|
|
MX2011009033A
(es)
*
|
2009-02-27 |
2011-09-15 |
Vertex Pharma |
Inhibidores triciclicos de cinasa pirazolopiridina.
|
|
WO2010100144A1
(en)
*
|
2009-03-04 |
2010-09-10 |
Merck Serono S.A. |
Fused bicyclic compounds as inhibitors for pi3 kinase
|
|
MX2011009796A
(es)
|
2009-03-20 |
2011-12-14 |
Amgen Inc |
Inhibidores de la cinasa pi3.
|
|
TW201103943A
(en)
|
2009-04-27 |
2011-02-01 |
Shionogi & Co |
Urea derivative having pi3k inhibitory activity
|
|
WO2010133534A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Cellzome Limited |
Bicyclic amino substituted compounds as pi3k inhibitors
|
|
EP2432782A1
(en)
|
2009-05-20 |
2012-03-28 |
Cellzome Ag |
Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
|
|
CN102459258B
(zh)
|
2009-06-05 |
2015-11-25 |
赛福伦公司 |
1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
|
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
|
MX2012000178A
(es)
|
2009-07-02 |
2012-02-28 |
Novartis Ag |
2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
|
|
US8293753B2
(en)
*
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
AR081823A1
(es)
|
2010-04-14 |
2012-10-24 |
Incyte Corp |
DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
|
|
US8487102B2
(en)
*
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
|
JP5583845B2
(ja)
|
2010-04-28 |
2014-09-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
イミダゾピリダジニル化合物および癌に対するそれらの使用
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
US9630956B2
(en)
|
2010-05-12 |
2017-04-25 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP5856151B2
(ja)
*
|
2010-05-12 |
2016-02-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
|
|
JP2013529200A
(ja)
*
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
US9096590B2
(en)
|
2010-05-24 |
2015-08-04 |
Intellikine Llc |
Substituted benzoxazoles as PI3 kinase inhibitors
|
|
AR081960A1
(es)
|
2010-06-22 |
2012-10-31 |
Fovea Pharmaceuticals Sa |
Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
|
|
EP2655374B1
(en)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
|
AU2012208693B2
(en)
*
|
2011-01-19 |
2015-02-26 |
Galapagos Nv |
Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
|
SI2694510T1
(sl)
|
2011-04-07 |
2016-02-29 |
Bayer Intellectual Property Gmbh |
Imidazopiridazini kot inhibitorji AKT kinaze
|
|
KR102507287B1
(ko)
|
2011-09-02 |
2023-03-07 |
인사이트 홀딩스 코포레이션 |
Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
|
|
WO2013049859A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
CA2869309C
(en)
|
2012-04-05 |
2021-02-09 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
|
JP6301316B2
(ja)
|
2012-05-23 |
2018-03-28 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
|
|
CN104619709B
(zh)
*
|
2012-07-13 |
2016-11-09 |
Ucb生物制药私人有限公司 |
作为tnf活性调节剂的咪唑并吡啶衍生物
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
WO2014144850A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
CN105164104B
(zh)
*
|
2013-03-20 |
2019-04-12 |
豪夫迈·罗氏有限公司 |
脲衍生物及其作为脂肪酸结合蛋白(fabp)抑制剂的用途
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
JP6496731B2
(ja)
|
2013-11-27 |
2019-04-03 |
シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
|
|
GB201321733D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
EP3105219B9
(en)
|
2014-02-13 |
2018-10-03 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
MX373103B
(es)
|
2014-02-13 |
2020-04-17 |
Incyte Holdings Corp |
Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
|
|
SI3105218T1
(sl)
|
2014-02-13 |
2019-11-29 |
Incyte Corp |
Ciklopropilamini kot inhibitorji LSD1
|
|
US9598424B2
(en)
|
2014-03-06 |
2017-03-21 |
Takeda Pharmaceutical Company Limited |
Heteroarylamide inhibitors of TBK1
|
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
AU2015366202B2
(en)
*
|
2014-12-19 |
2020-01-02 |
Janssen Pharmaceutica Nv |
Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors
|
|
SI3831833T1
(sl)
|
2015-02-27 |
2023-03-31 |
Incyte Holdings Corporation |
Postopki za pripravo inhibitorja PI3K
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
LT3334709T
(lt)
|
2015-08-12 |
2025-03-10 |
Incyte Holdings Corporation |
Lsd1 inhibitoriaus druskos
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
CA3016161A1
(en)
|
2016-03-03 |
2017-09-08 |
Cornell University |
Small molecule ire1-alpha inhibitors
|
|
JP6999574B2
(ja)
|
2016-04-22 |
2022-01-18 |
インサイト・コーポレイション |
Ｌｓｄ１阻害剤の製剤
|
|
WO2018013430A2
(en)
|
2016-07-12 |
2018-01-18 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus infection
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
WO2018140513A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
US10669246B2
(en)
*
|
2017-10-02 |
2020-06-02 |
1ST Biotherapeutics, Inc. |
Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
|
|
HUE058292T2
(hu)
*
|
2017-10-30 |
2022-07-28 |
Bristol Myers Squibb Co |
Aminoimidazopiridazinok mint kináz inhibitorok
|
|
EP3728228A1
(en)
|
2017-12-22 |
2020-10-28 |
Ravenna Pharmaceuticals, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
BR112020012651A2
(pt)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
|
|
WO2019149965A1
(en)
*
|
2018-02-05 |
2019-08-08 |
Universite De Strasbourg |
Compounds and compositions for the treatment of pain
|
|
CN113194752A
(zh)
|
2018-06-01 |
2021-07-30 |
康奈尔大学 |
Pi3k相关疾病或病症的组合疗法
|
|
CA3101323A1
(en)
|
2018-06-01 |
2019-12-05 |
Incyte Corporation |
Dosing regimen for the treatment of pi3k related disorders
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
US12419865B2
(en)
|
2018-12-06 |
2025-09-23 |
Arisan Therapeutics Inc. |
Compounds for the treatment of arenavirus infection
|
|
US11098044B2
(en)
|
2019-02-22 |
2021-08-24 |
1ST Biotherapeutics, Inc. |
Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
|
|
KR20210126146A
(ko)
*
|
2019-03-07 |
2021-10-19 |
주식회사 퍼스트바이오테라퓨틱스 |
Pet 방사선추적자로서의 [18f]-라벨링된 벤조티아졸 유도체
|
|
US10385046B1
(en)
|
2019-03-19 |
2019-08-20 |
1ST Biotherapeutics, Inc. |
Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
|
|
JP7604387B2
(ja)
*
|
2019-03-28 |
2024-12-23 |
ファースト・バイオセラピューティクス・インコーポレイテッド |
ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
|
|
CN113905787A
(zh)
*
|
2019-04-05 |
2022-01-07 |
斯托姆治疗有限公司 |
Mettl3抑制化合物
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
WO2021138391A1
(en)
|
2019-12-30 |
2021-07-08 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
CN112047950B
(zh)
*
|
2020-09-14 |
2023-07-25 |
华东师范大学 |
咪唑并吡嗪类衍生物及其合成方法和应用
|
|
EP4214207A4
(en)
|
2020-09-15 |
2024-10-02 |
1st Biotherapeutics, Inc. |
2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS
|
|
IL301244A
(en)
*
|
2020-09-28 |
2023-05-01 |
1St Biotherapeutics Inc |
INDOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING THEM
|
|
BR112023005876A2
(pt)
|
2020-09-30 |
2023-05-02 |
Sumitomo Chemical Co |
Composto heterocíclico e composição de controle de artrópode nocivo contendo o mesmo
|
|
WO2023134692A1
(zh)
*
|
2022-01-13 |
2023-07-20 |
浙江同源康医药股份有限公司 |
多环类化合物及其用途
|
|
CN115850263B
(zh)
*
|
2022-12-28 |
2025-06-17 |
浙江工业大学 |
一种2,7-二取代苯并噻唑类化合物及其应用
|
|
CN119841829A
(zh)
*
|
2023-10-18 |
2025-04-18 |
中国科学院合肥物质科学研究院 |
用于治疗PI3Kγ介导的疾病的化合物及其用途
|